Beside the proper production of drug substance, developing a suitable formulation is crucial for ensuring the activity and stability of the final drug product. For this, it is essential to gain maximum knowledge about the potential degradation pathways and how to address such degradation analytically.
Selvita supports its clients in the early stages of pre-formulation screening and pre-clinical formulation development: Forced degradation and stability studies in combination with the application of appropriate stability-indicating methods facilitate the identification of possible degradation products. One major advantage is Selvita’s comprehensive state-of-the-art portfolio matching the requirements for small molecule analytics as well as for in-depth characterization of peptides and recombinant proteins.
With over 15 years of experience in supporting its international pharmaceutical and biotechnological customers in the field of R&D and QC analytics, Selvita is looking forward to accelerate your formulation development approach.